August 23, 2018 / 11:16 AM / 3 months ago

BRIEF-Roche Receives FDA Approval For Cobas EGFR Mutation Test v2 As Companion Diagnostic With IRESSA

Aug 23 (Reuters) - Roche Holding AG:

* ROCHE RECEIVES FDA APPROVAL FOR COBAS EGFR MUTATION TEST V2 AS COMPANION DIAGNOSTIC WITH IRESSA (GEFITINIB) IN FIRST-LINE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

* ROCHE HOLDING AG - APPROVAL FOR USE OF EITHER TUMOUR TISSUE OR PLASMA BIOPSY PROVIDES PATIENTS AND CLINICIANS A NON-INVASIVE SAMPLE COLLECTION OPTION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below